JPRN-jRCT2080221733未知3 期
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)
ovartis Pharma K.K.0 个研究点开始时间: 2012年3月5日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects must have participated in the study CAIN457A2304 and have achieved a partial response after twelve weeks of treatment with no major protocol deviations.
- •A partial response is defined as having achieved >= PASI 50 but < 75 response.
排除标准
- •-Forms of psoriasis other than chronic plaque -type
- •-Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304
研究者
相似试验
已完成
2 期
Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.Iron overload..Abnormal level of blood mineral.IRCT201206289827N2Kermanshah University of Medical Sciences and Health Services42
尚未招募
4 期
Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled TrialCTRI/2020/02/023125Department of Obstetrics And Gynecology
尚未招募
3 期
Comparison of efficacy and safety of two modes of Autologous Serum Therapy injectioCTRI/2024/02/062280Mythraye B
尚未招募
4 期
Comparing Tramadol vs Paracetamol for Pain Relief in Acute Pancreatitis: A Randomized Controlled TrialCTRI/2024/06/068751DR ABHIJEET SHRIDHAR
已完成
2 期
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80